CORD-19:16a812de72963ceda960a168236e8dbe91832d45 / 73759-73985 JSONTXT

{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T126","span":{"begin":0,"end":226},"obj":"Sentence"}],"text":"Seventh, FACS using fluorescently labeled tetramers of VP2 121-130 /D b demonstrate that 60% to 80% of all CD8 + T-cells in the CNS of infected mice are directed against this one immunodominant peptide (Johnson et al., 1999) ."}

{"project":"CORD-19-Sentences","denotations":[{"id":"TextSentencer_T368","span":{"begin":0,"end":226},"obj":"Sentence"},{"id":"TextSentencer_T368","span":{"begin":0,"end":226},"obj":"Sentence"},{"id":"T71821","span":{"begin":0,"end":226},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Seventh, FACS using fluorescently labeled tetramers of VP2 121-130 /D b demonstrate that 60% to 80% of all CD8 + T-cells in the CNS of infected mice are directed against this one immunodominant peptide (Johnson et al., 1999) ."}

{"project":"CORD-19-PD-MONDO","denotations":[{"id":"T215","span":{"begin":9,"end":13},"obj":"Disease"}],"attributes":[{"id":"A215","pred":"mondo_id","subj":"T215","obj":"http://purl.obolibrary.org/obo/MONDO_0018262"}],"text":"Seventh, FACS using fluorescently labeled tetramers of VP2 121-130 /D b demonstrate that 60% to 80% of all CD8 + T-cells in the CNS of infected mice are directed against this one immunodominant peptide (Johnson et al., 1999) ."}

{"project":"CORD-19-PD-UBERON","denotations":[{"id":"T155","span":{"begin":128,"end":131},"obj":"Body_part"}],"attributes":[{"id":"A155","pred":"uberon_id","subj":"T155","obj":"http://purl.obolibrary.org/obo/UBERON_0001017"}],"text":"Seventh, FACS using fluorescently labeled tetramers of VP2 121-130 /D b demonstrate that 60% to 80% of all CD8 + T-cells in the CNS of infected mice are directed against this one immunodominant peptide (Johnson et al., 1999) ."}